Oracle and Oxford Nanopore Partner to Improve Healthcare and Accelerate Discovery of New Medical Advances

0

Technology leaders will jointly explore high-performance DNA / RNA sequencing solutions accessible and powered by Oracle Cloud Infrastructure (OCI) to improve patient care and outcomes

AUSTIN, Texas, September 16, 2021 / PRNewswire / – Advances in DNA / RNA sequencing promise to revolutionize the way medical communities identify, detect and treat disease and manage threats to public health. To make this technology more accessible and increase its impact, Oracle has partnered with Oxford Nanopore Technologies, the company behind a new generation of high-performance, fast, scalable and accessible sequencing technology.

Oracle Logo (PRNewsfoto / Oracle)

Oracle and Oxford Nanopore recently started a collaboration to jointly explore several potential new solutions that would use genomic sequencing performed on Oracle Cloud Infrastructure (OCI) to accelerate medical breakthroughs and improve patient care.

Scientific researchers from more than 100 countries are already using nanopore sequencing to deepen their understanding of biology in various fields, including human and cancer genetics as well as plant, animal and environmental analyzes. In addition, nanopore sequencing has been used for pathogen analysis, including outbreak surveillance of tuberculosis, foodborne pathogens, Ebola, Zika, Lassa fever, dengue, influenza and, more recently, COVID-19.

As part of this collaboration, Oxford Nanopore will use OCI in the applied and clinical markets. By leveraging the high performance, security and extended reach of Oracle Cloud, Oracle and Oxford Nanopore will have the ability to extend population-wide gene sequencing across the globe.

The organizations will also undertake several ambitious projects spanning epidemiology, whole genome sequencing, healthcare and drug discovery. This includes the integration of Oxford Nanopore’s DNA / RNA sequencing capabilities and data into Oracle’s broad healthcare portfolio and life science applications strengthen the links between genomics, medical treatment and drug development.

“Oxford Nanopore’s innovative sequencing technology is unmatched in the market for its ability to generate rich and precise genomic data at any scale, from portable devices to very high throughput facilities,” said Mike Sicily, executive vice president of Oracle Vertical Industries. “By integrating genomic data into our existing applications and cloud infrastructure solutions, we can put these powerful tools in the hands of more people to resolve critical health issues faster and improve patient outcomes. to usher in a new era of genomic breakthrough. “

At the same time, Oracle has pledged to invest £ 150million in Oxford Nanopore, subject to customary conditions.

About Oracle
Oracle offers integrated application suites as well as secure, stand-alone infrastructure in Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.

Brands
Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.

Safe Harbor Declaration
This press release contains forward-looking statements, including, but not limited to, statements relating to (1) a memorandum of understanding between Oracle and Oxford Nanopore Technologies, whereby the two companies will jointly explore a number of potential new solutions for seize opportunities in applied areas and clinical markets and associated go-to-market strategies, including Oxford Nanopore Technologies’ migration of its EPI2ME platform to Oracle Cloud Infrastructure and (2) Oracle’s commitment to invest $ 150 million at Oxford Nanopore Technologies. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The degree of collaboration of the parties, the migration of the platform and the success of the foregoing, as well as the consumption of the investment, are subject to many factors that could cause actual results to differ materially. A detailed discussion of these and other risks that affect our business is contained in our documents with the SEC, including our most recent reports on Forms 10-K and 10-Q, particularly under the heading “Factors risk ”. All information in this press release is current as of September [13], 2021. Oracle does not undertake to update any statement in light of new information or future events.

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-oxford-nanopore-team-up-to-improve-healthcare-and-speed-discovery-of-new-medical-breakthroughs-301378279.html

SOURCE Oracle


Source link

Share.

Leave A Reply